USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: NAVIDEA BIOPHARMACEUTICALS, INC.
City: DUBLIN
State: OH
Zip+4: 43017
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: http://www.navidea.com
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $725,855.00 3

Award List:

CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Frederick O. Cope – 614-822-2320
Award Amount: $315,217.00
Abstract:
DESCRIPTION (provided by applicant): After an interim period of inactivity based on a select alternative commercial focus, and after consultation with the FDA, Neoprobe Corporation is rapidly reinitiating efforts to develop and commercialize 125Iodine-labeled HuCC49 CH2 anti-Tumor Associated… More

Beta Amyloid Deposits Imaged with 18F-AZD4694 and Postmortem Histology

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Frederick O. Cope – 617-822-2330
Award Amount: $258,824.00
Abstract:
DESCRIPTION (provided by applicant): Navidea Biopharmaceuticals is developing 18F-AZD4694 as a diagnostic imaging agent to be used with PET scans to directly visualize beta amyloid (A ) deposits in the brains of living patients. A deposits in the brains of patients with dementia are diagnostic for… More

A peripheral diagnostic biomarker for Major Depressive Disorder

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Frederick O. Cope – 614-822-2330
Award Amount: $151,814.00
Abstract:
DESCRIPTION (provided by applicant): Navidea Biopharmaceuticals is developing [18F]NAV4694 as a diagnostic imaging agent that can be used to visualize beta-amyloid (A) plaques in the brains of living individuals. Alzheimer's disease is the leading cause ofdementia. All patients with dementia… More